| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4753
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate |
1995-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1997-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_058623d52b687eacfb920f119a2a9405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_852892045e860735ea6308a58d50964c |
| publicationDate |
1997-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5703048-A |
| titleOfInvention |
Protection against liver damage by HGF |
| abstract |
The present invention provides methods for preventing occurrence or progression of liver damage using hepatocyte growth factor. In the methods, a preventatively effective amount of the hepatocyte growth factor is administered to the patient. The hepatocyte growth factor can be administered, for instance, prior to administering a hepatotoxic therapy to the patient. The hepatocyte growth factor can further be administered with activin or transforming growth factor-beta to prevent liver damage. Compositions comprising hepatocyte growth factor and activin antagonist or transforming growth factor-beta antagonist are also provided by the invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006193827-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003082134-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0109368-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7306791-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7138372-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7115568-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8227404-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8193173-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011189709-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6436388-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5928167-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5998370-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8575088-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6869609-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008293799-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009226460-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009176702-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003153489-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005250686-A1 |
| priorityDate |
1992-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |